Dublin, June 17, 2022 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Predictive Genetic Testing, AI-enabled Drug Discovery, Circular RNA, and Advanced Drug Delivery" report has been added to ResearchAndMarkets.com's offering.
The report focuses on technology platforms that leverage AI and ML algorithms for novel target discovery and drug development applications. A key focus of this issue is on precision oncology tests and other predictive genetic tests for multiple therapeutic applications. In particular, technologies which enable early diagnosis of cancers, support biomarker discovery and disease prognosis have been covered.
Another focus of this issue is on advanced RNA therapeutics, including circular RNA and self-replicating RNAs which offer several advantages of conventional mRNA based therapeutics. In addition, advanced drug delivery using engineered cells and biosensors for monitoring therapy efficacy and response have been captured.
The report features disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
1. Innovations in Life Sciences, Health & Wellness
Machine Learning (ML) Model Based in Vitro Cellular Systems for Drug Discovery and Development
Identifying Disease-Modifying Targets
Insitro - Investor Dashboard
Generating Artificial Intelligence (AI)-Driven Precision Disease Models to Develop Targeted Therapies
Generating Precise Organ-Specific Disease Modeling
Genome Biologics - Dashboard
Tapping into the Unexplored Biological Networks in Age-Related Diseases
Using Omics Data to Track Aging
BioAge Labs - Investor Dashboard
Using Small RNA (sRNA) Signatures to Provide Insights on Targetable Pathways for Drug Development
Addressing Chronic Degenerative Diseases
Gatehouse Bio - Investor Dashboard
Synthetic Circular RNA-based Therapeutics
Promising Alternative to Conventional Messenger RNA
Orna Therapeutics, Inc. - Investor Dashboard
srRNA Platform Preventing the Onset of Cancer Drug Resistance
srRNA Enabling Sustained Therapeutic Protein Expression
Replicate Bioscience - Investor Dashboard
Programmable Circular RNA Therapeutics
A Single Therapy Catering to Multiple Disease Areas
Laronde - Investor Dashboard
Next-Generation Sequencing-Based Tests for Genetic Disorders
Whole Exome Sequencing Identifying DNA Variants
Berry Genomics - Investor Dashboard
Precision Oncology Health Intelligence Platform
Technology Enabling Comprehensive Panel for Cancer Profiling
Sema4 Opco, Inc. - Investor Dashboard
Red Blood Cell-based Platform Inducing the Immune System to Protect Against COVID-19
Technology Value Proposition of McMaster University
Nanoparticles Conjugated With Regulatory Proteins Evading Immune System Attacks to Deliver Nanomedicines
Technology Value Proposition of University of Pennsylvania
An Advanced Tool Expediting Crop Genomic Experiments
Technology Value Proposition of CABBI
Assessing Immune Checkpoint Blockade (ICB) Therapy for Cancer With Biosensors
Georgia Institute of Technology's Technology Value Proposition
Orna Therapeutics, Inc.
Sema4 Opco, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jc331h
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900